• PAD4-IN-2 TFA: Targeting the PAD4–NET Axis

  2026-09-18

  A translational analysis of PAD4-IN-2 TFA, also known as Compound 5i TFA, focusing on tumor-biased uptake, H3cit and NET biology, assay design, immune-context interpretation, and the strategic path from preclinical evidence to better PAD4 research decisions.

• Cepharanthine Inhibits Endometriosis via Apoptosis

  2026-09-18

  A 2026 reference study tested Cepharanthine across immortalized stromal cells, patient-derived endometriotic cells, endometrial organoids, and a murine peritoneal model. The results connect reduced lesion growth with G0/G1 arrest, DNA damage, impaired repair, and mitochondrial apoptosis, while supporting organoids as a useful bridge between cell-based screening and in vivo validation.

• CTOP: μ-Opioid Receptor Antagonist Workflows

  2026-09-17

  CTOP provides a selective pharmacological control for separating μ-opioid receptor activity from downstream pain-circuit effects. This guide translates recent mouse findings into practical cell, tissue, and localized neuropharmacology workflows, with controls and troubleshooting strategies for mechanical hypersensitivity and tolerance studies.

• LPS Protection of Macrophages Against Chemotherapy

  2026-09-17

  The reference study identifies a protective response in macrophages in which lipopolysaccharide promotes system Xc− activity, glutathione maintenance, and ABCC1-associated drug handling during antitumor drug exposure. Its main contribution is to connect immune-cell protection with redox and transporter biology while emphasizing that LPS did not provide the same protection to tumor cells.

• FOXM1–ERα Networks in Female Lung Adenocarcinoma

  2026-09-16

  The reference study integrates public transcriptomic datasets, ceRNA modeling, immune analyses, and cell experiments to examine FOXM1 in female lung adenocarcinoma. Its main contribution is a testable FOXM1–miR-204-5p–estrogen receptor network hypothesis, while its findings also identify important limits that must be addressed before clinical or mechanistic translation.

• Cannabidiol for Orofacial Pain: Mechanisms and Evidence

  2026-09-16

  A 2026 Brain Research Bulletin study shows that cannabidiol reduces inflammatory pain while also improving anxiety-, depression-, and cognition-related deficits in mice. Its main contribution is a mechanistic framework linking peripheral CB2 signaling, central CB1-dependent endocannabinoid activity, and serotonin dynamics in the central amygdala.

• SAMe and Methylation in Neurological Disorders

  2026-09-15

  The 1994 review by Bottiglieri, Hyland, and Reynolds frames ademetionine (S-adenosylmethionine; SAMe) as a central methyl donor linking folate and vitamin B12 metabolism with neurotransmitter regulation and neurological disease. Its main practical contribution is a biochemical-to-clinical framework for interpreting SAMe abnormalities across depression, dementia, demyelination, epilepsy, and selected metabolic or treatment-associated encephalopathies, while emphasizing that much of the therapeutic evidence was preliminary.

• Resiquimod (R-848) in Tumor Ablation Research

  2026-09-15

  Resiquimod (R-848) links TLR7/8-driven innate immune response modulation with thermal ablation and programmable local delivery. This workflow explains how to control solubility, separate heat and drug effects, and translate immune readouts into cancer immunotherapy research decisions.

• Valemetostat (DS-3201) EZH2 Research Workflow

  2026-09-14

  Valemetostat (DS-3201) is a practical epigenetic tool for connecting EZH2 inhibition with lymphoma-cell phenotypes, mutant-enzyme profiling, and mechanistic biomarker assays. This workflow emphasizes exposure control, orthogonal readouts, and troubleshooting for translational research rather than clinical dosing.

• HBV Resistance After Entecavir or Tenofovir

  2026-09-14

  This 2024 systematic review and random-effects meta-analysis provides the first pooled estimates of sequence-defined hepatitis B virus resistance during Entecavir or tenofovir therapy. It shows a low resistance risk in treatment-naive patients receiving Entecavir, but substantially higher and imprecisely estimated resistance among patients with prior nucleos(t)ide exposure, highlighting the need for better prospective surveillance.

• ORAI2 and Early Postirradiation Salivary Fibrosis

  2026-09-13

  The reference study identifies ORAI2-dependent store-operated calcium entry as an early driver of postirradiation salivary gland fibrosis and defines an ORAI2/JNK/NFAT1/TGF-β1 signaling axis. Its combined cell, mouse, transcriptomic, and pharmacological design supports calcium signaling as a mechanistic target while also highlighting the need for pathway-level rather than ORAI2-specific interpretation of SOCE inhibitors.

• SB 431542 for Reliable Cell Assays

  2026-09-12

  A scenario-based guide to using SB 431542 (SKU A8249) as a selective ALK5 inhibitor in proliferation, viability, and immunology workflows. It connects mechanism, assay controls, formulation, storage, interpretation, and vendor selection to practical laboratory decisions.

• C34 TLR4 Inhibitor: Evidence and Workflow

  2026-09-11

  C34 is a selective small molecule TLR4 inhibitor for inflammatory signaling research. Product information reports functional inhibition near 10 μM in vitro and activity near 1 mg/kg in endotoxemia and necrotizing enterocolitis models, while peer-reviewed work uses C34 as a TLR4 reference inhibitor in microglial assays.

• NETs and IL-36R Feedback in Psoriasis

  2026-09-11

  The reference study defines a mechanistic link between TLR3/P2X7R-driven NETosis and IL-36R-dependent inflammatory amplification in psoriasiform disease. Its combined neutrophil, keratinocyte, receptor-deficiency, and imiquimod-model experiments suggest that interrupting NET formation or IL-36R signaling may reduce inflammatory feedback, while also highlighting important limits of translating acute mouse models to human psoriasis.

• Ginsenoside Rg1 in Neuroprotection Workflows

  2026-09-10

  Ginsenoside Rg1 provides a practical way to connect behavioral, synaptic, inflammatory, and gut-barrier measurements in anesthesia-related neuroprotection research. This workflow translates Treg-dependent gut–immune–brain findings into formulation controls, assay choices, and troubleshooting checkpoints.

8391 records 4/560 page Previous Next 12345 下5页 Last page